Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Implantable Drug Delivery Systems Market $33.5 Billion by 2027

The global market for implantable drug delivery systems expected to cross $33.5 billion by 2027, growing at a CAGR of 5.8% over the forecast period, driven by increasing demand for minimal invasive technologies, and improved efficiency, higher effectiveness, reduced side effects, and convenient therapy options.

  • Other factors boosting the market growth include growing elderly population, increasing prevalence of cardiovascular diseases, prostate cancer, cervical cancer, breast cancer, colorectal cancer, chronic pain-causing disorders, diabetes and diabetic retinopathy, and unwanted pregnancies, globally.
Global Implantable Drug Delivery Systems Market

Implantable drug delivery systems (IDDSs) offer physicians the choice of precision delivery, either locally or into systemic circulation, while guaranteeing optimal dosing over the course of treatment. IDDSs are bioengineering devices surgically placed inside the patient’s tissues to avoid first-pass metabolism and reduce the systemic toxicity of the drug by eluting the therapeutic payload in the vicinity of the target tissues. It is envisaged that the IDDS technologies will grow exponentially in the coming years.

  • The major advantage of these systems includes targeted local delivery of the drug at a constant and predetermined rate, thereby minimizing dose required and potential side effects, while improving therapeutic efficacy.
  • The precise distribution of the drug to the target tissue without bioavailability and first-pass metabolism concerns allows reduction in the active dosage; minimization of side effects due to lower active substance systemic concentrations and absence of risk of incorrect drug administration; prolonged and dose-controlled delivery of the drug, which makes the therapy independent of patient compliance.
    • Moreover, there are numerous possibilities for the smart IDDS equipped with sensors and feedback-controlled drug release IDDS, i.e., epileptic seizure preventing implants or insulin pumps with glucose level analyzers

The implantable therapeutic devices are mainly used for long term, continuous drug administration, and controlled release. This method is also relatively less expensive and less wasteful of the drug. The dosage requirements often are lower than alternatives, further reducing the potential for side effects. The IDDSs that reached the clinical and market stage can be broadly classified as inserts, pumps, and stents.

  • The main therapeutic payloads that are delivered by an IDDS include hormonal, cytostatic, anticoagulant, antipsychotic, and metabolic drugs. There are also several emerging fields of IDDSs’ clinical use appeared at the advanced stages of clinical trials, e.g., mental health disorders.
    • For example, the applications of implantable drug-eluting devices include, among others, diabetes management, contraception, HIV/AIDS prevention, chronic pain management, cardiology, oncology, and central nervous system (CNS) health.
    • Along with subcutaneous implantation, various body regions can serve as implantation sites (e.g., intravaginal, intravascular, intraocular, intrathecal, and peritoneal). 
      • These systems are particularly useful for diseases requiring long-term therapy or facing challenges with patient compliance, such as cardiovascular disease, tuberculosis, diabetes, cancer, and chronic pain management.
Implantable Drug Delivery Devices Market

The global implantable drug delivery devices market report provides market size estimates ($million 2017 to 2027), market share, growth trends and forecast (CAGR% 2021 to 2027).

The global market for implantable drug delivery devices segmented by product [bio-absorbable stents, brachytherapy seeds (iodine-125, cesium-131, palladium-103, iridium-192, others), contraceptive devices (intravaginal ring, hormonal IUD, subdermal contraceptive implants), coronary drug eluting stents, drug infusion pumps, intraocular devices], technology (biodegradable drug delivery, non-biodegradable drug delivery), application [birth control (contraception), cardiovascular, oncology, ophthalmology, others (diabetes, chronic pain)] , and geography.

  • Based on the products, the coronary drug eluting stents segment accounted for more than 60% share of the total market, attributed to increasing incidences of cardiovascular diseases.
    • The drug eluting stents (DES) mitigate side effects such as stent thrombosis and restenosis associated with percutaneous coronary intervention (PCI).
      • However, the introduction of technologically advanced bio-absorbable stents segment expected to outperform the market for the conventional drug eluting stents during the forecast period.
  • Among the contraceptive products segment, the hormonal Intrauterine device sub-segment registered the highest market revenue with a potential to grow at the fastest rate over the next few years.
  • In terms of technology, the non-biodegradable drug delivery devices segment dominated the total market, whereas the biodegradable drug delivery devices segment forecast to witness the fastest growth rate during the near future.
  • By applications, the cardiovascular implantable drug delivery devices segment recorded the majority share of market revenue and also anticipated grow at the fastest CAGR over the forecast period, due to unmet medical needs, large patient pool and technologically advanced products.

The global market for implantable drug delivery systems research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • Geographically, the North America region dominated the total market, followed by the Europe region, owing to rapid adoption of technologically advanced products, increasing consumer awareness, and sophisticated healthcare infrastructure in these regions.
    • However, the Asia Pacific region expected to be the most attractive market growing at the fastest rate in the coming years, due to rapidly aging population, presence of high unmet medical needs and rising disposable income in the emerging nations.

The global research report also provides detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and/or services offered, and recent trends in strategic management.

Major competitors operating in the global market for implantable drug delivery systems and included in this report are Abbott Laboratories, Inc., Allergan, Inc. (TARIS Biomedical), Bausch Health Companies, Inc. (Bausch + Lomb), Bayer AG, Boston Scientific Corporation, Elekta AB (Nucletron Operations B.V.), EyePoint Pharmaceuticals, Inc. (pSivida Corporation), Medtronic plc, and Merck & Co., Inc.

Other market players include Analogic Corp. (Oncura Partners Diagnostics), Axxia Pharmaceuticals, LLC, Becton, Dickinson and Company (C. R. Bard, Inc.), Core Oncology, Inc., Delpor, Inc., Eckert & Ziegler Bebig SA, Endo International plc (Endo Pharmaceuticals), Intarcia Therapeutics, Inc., Integra LifeSciences, J3 Bioscience, Inc., Nano Precision Medical, Pfizer, Inc. Siemens Healthineers AG (Varian Medical Systems, Inc.), Titan Pharmaceuticals, Inc., Theragenics Corporation, and ViaCyte, Inc.

  • Product
    • Bio-Absorbable Stents
    • Brachytherapy Seeds
      • Iodine-125
      • Cesium-131
      • Palladium-103
      • Iridium-192
      • Others
    • Contraceptive Devices
      • Intravaginal Ring
      • Hormonal IUD
      • Subdermal Contraceptive Implants
    • Coronary Drug Eluting Stents
    • Drug Infusion Pumps
    • Intraocular Devices
  • Technology
    • Biodegradable Drug Delivery Technology
    • Non-Biodegradable Drug Delivery Technology
  • Application
    • Birth Control (Contraception)
    • Cardiovascular
    • Oncology
    • Ophthalmology
    • Others (Diabetes, Chronic Pain)
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Abbott Laboratories, Inc.
    • Allergan, Inc. (TARIS Biomedical)
    • Analogic Corp. (Oncura Partners Diagnostics)
    • Axxia Pharmaceuticals, LLC
    • Bausch Health Companies, Inc. (Bausch + Lomb)
    • Bayer AG
    • Becton, Dickinson and Company (C. R. Bard, Inc.)
    • Boston Scientific Corporation
    • Core Oncology, Inc.
    • Delpor, Inc.
    • Eckert & Ziegler Bebig SA
    • Elekta AB (Nucletron Operations B.V.)
    • Endo International plc (Endo Pharmaceuticals)
    • EyePoint Pharmaceuticals, Inc. (pSivida Corporation)
    • Intarcia Therapeutics, Inc. 
    • Integra LifeSciences
    • J3 Bioscience, Inc.
    • Medtronic plc
    • Merck & Co., Inc.
    • Nano Precision Medical
    • Pfizer, Inc.
    • Siemens Healthineers AG (Varian Medical Systems, Inc.)
    • Titan Pharmaceuticals, Inc.
    • Theragenics Corporation
    • ViaCyte, Inc.

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]